UA93883C2 - Производные пиразина, полезные kak антагонисты аденозинового рецептора - Google Patents

Производные пиразина, полезные kak антагонисты аденозинового рецептора

Info

Publication number
UA93883C2
UA93883C2 UAA200802498A UAA200802498A UA93883C2 UA 93883 C2 UA93883 C2 UA 93883C2 UA A200802498 A UAA200802498 A UA A200802498A UA A200802498 A UAA200802498 A UA A200802498A UA 93883 C2 UA93883 C2 UA 93883C2
Authority
UA
Ukraine
Prior art keywords
receptor antagonists
iiа
adenosine receptor
derivatives useful
pyrazine derivatives
Prior art date
Application number
UAA200802498A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хуан Бернат Видаль
Триас Кристина Эстеве
Пуэйо Лидия Сока
Пол Роберт Иствуд
Original Assignee
Лабораториос Алмиралл, C.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35945119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93883(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лабораториос Алмиралл, C.A. filed Critical Лабораториос Алмиралл, C.A.
Publication of UA93883C2 publication Critical patent/UA93883C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA200802498A 2005-07-29 2006-07-25 Производные пиразина, полезные kak антагонисты аденозинового рецептора UA93883C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200501876A ES2270715B1 (es) 2005-07-29 2005-07-29 Nuevos derivados de pirazina.

Publications (1)

Publication Number Publication Date
UA93883C2 true UA93883C2 (ru) 2011-03-25

Family

ID=35945119

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200802498A UA93883C2 (ru) 2005-07-29 2006-07-25 Производные пиразина, полезные kak антагонисты аденозинового рецептора

Country Status (22)

Country Link
US (2) US7790728B2 (ru)
EP (1) EP1922313A1 (ru)
JP (1) JP2009502837A (ru)
KR (1) KR20080040681A (ru)
CN (1) CN101268064A (ru)
AR (1) AR056008A1 (ru)
AU (1) AU2006278875A1 (ru)
CA (1) CA2616428A1 (ru)
EC (1) ECSP088113A (ru)
ES (1) ES2270715B1 (ru)
IL (1) IL188725A0 (ru)
MX (1) MX2008001035A (ru)
NO (1) NO20080451L (ru)
NZ (1) NZ565150A (ru)
PE (1) PE20070407A1 (ru)
RU (1) RU2417994C2 (ru)
SG (1) SG162805A1 (ru)
TW (1) TW200728299A (ru)
UA (1) UA93883C2 (ru)
UY (1) UY29672A1 (ru)
WO (1) WO2007017096A1 (ru)
ZA (1) ZA200800353B (ru)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556732A (en) 2005-01-25 2011-11-25 Synta Pharmaceuticals Corp Pyrazine compounds for inflammation and immune-related uses
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP2078016B1 (en) 2006-10-19 2012-02-01 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CA2716223A1 (en) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
JP5460690B2 (ja) 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
KR101677778B1 (ko) 2009-02-06 2016-11-18 니뽄 신야쿠 가부시키가이샤 아미노피라진 유도체 및 의약
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2338890A1 (en) 2009-12-22 2011-06-29 Bayer CropScience AG 4,7-Diazaindole derivatives and their use as fungicides
CN102822150B (zh) * 2010-02-05 2014-12-03 赫普泰雅治疗有限公司 1,2,4-三嗪-4-胺衍生物
CN101817823B (zh) * 2010-03-31 2012-09-12 上海毕得医药科技有限公司 4，7-二氮杂吲哚及其5位取代物的制备方法
RS55856B1 (sr) 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
JP5827998B2 (ja) 2010-09-13 2015-12-02 アドヴィナス・セラピューティックス・リミテッド Ａ２ｂアデノシン受容体アンタゴニストのプロドラッグとしてのプリン化合物、これらの方法および薬剤の適用
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
TWI659030B (zh) * 2011-10-26 2019-05-11 諾華公司 Ｉｐ受體促效劑雜環化合物
CN104169282B (zh) * 2012-01-13 2016-04-20 诺华股份有限公司 Ip受体激动剂的盐
EP2802585A1 (en) * 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
US20140378463A1 (en) * 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
EP2802582A1 (en) * 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
ES2565826T3 (es) * 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
US20150005311A1 (en) * 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
EP2857398A4 (en) 2012-05-30 2015-11-11 Nippon Shinyaku Co Ltd AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL PRODUCT
SG11201408238WA (en) 2012-06-13 2015-01-29 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9255105B2 (en) * 2012-12-06 2016-02-09 Enaltec Labs Private Limited Process of preparing alcaftadine
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
CN103364500B (zh) * 2013-06-29 2019-01-22 北京万全德众医药生物技术有限公司 一种用液相色谱法分离测定比拉斯汀原料及其制剂的方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JP6779204B2 (ja) * 2014-11-18 2020-11-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ａ２ａ拮抗薬特性を有するアミノピラジン化合物
CN104447585B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 吡嗪类化合物及其组合物及用途
CN104402833B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447583B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447584B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104496918B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 吡嗪衍生物及其用途
AU2015370911B2 (en) 2014-12-23 2020-07-09 Bergenbio Asa Inhibitors of Akt kinase
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2580702B1 (es) * 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7013213B2 (ja) * 2017-05-26 2022-01-31 日本化薬株式会社 ピラジン化合物
MX2020000693A (es) 2017-07-18 2020-07-29 Nuvation Bio Inc Compuestos de 1,8-naftiridinona, y usos de los mismos.
JP2020527588A (ja) * 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． アデノシンアンタゴニストとしてのヘテロ環式化合物
CA3097752A1 (en) * 2018-04-20 2019-10-24 Virginia Tech Intellectual Properties, Inc. Imidazopyridines useful as mitochondrial uncouplers
WO2019213506A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
CN109020881B (zh) * 2018-06-28 2020-04-28 新发药业有限公司 一种阿帕替尼的制备方法
CN112279837B (zh) * 2018-08-17 2022-08-09 迪哲(江苏)医药股份有限公司 吡嗪化合物和其用途
JP7510426B2 (ja) 2018-10-24 2024-07-03 リードエックスプロ アーゲー 官能化されたアミノトリアジン
EP3904352A4 (en) * 2018-12-28 2022-09-07 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ARYL SUBSTITUTED COMPOUND, METHOD FOR THE PREPARATION AND USE THEREOF
CN111377873B (zh) * 2018-12-28 2023-03-28 四川科伦博泰生物医药股份有限公司 氨基嘧啶化合物及其制备方法和用途
CN111377906B (zh) * 2018-12-28 2022-09-02 四川科伦博泰生物医药股份有限公司 取代的吡嗪化合物及其制备方法和用途
MX2021008650A (es) 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
CN113631167A (zh) * 2019-01-18 2021-11-09 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
CN113939291A (zh) 2019-01-18 2022-01-14 诺维逊生物股份有限公司 1,8-萘啶酮化合物及其用途
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110407677B (zh) * 2019-06-17 2022-10-11 南京先进生物材料与过程装备研究院有限公司 二苯乙二酮类化合物的制备方法及应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112592346B (zh) * 2019-07-30 2022-04-26 厦门宝太生物科技股份有限公司 一种a2a和/或a2b抑制剂中间体的制备方法
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021146631A1 (en) * 2020-01-17 2021-07-22 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2021146629A1 (en) * 2020-01-17 2021-07-22 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309573D0 (en) 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
JP2000506532A (ja) 1996-03-13 2000-05-30 スミスクライン・ビーチャム・コーポレイション サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
ES2304797T3 (es) 1997-12-19 2008-10-16 Amgen Inc. Compuestos de piridina y piridazina sustituidos y su uso farmaceutico.
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
AU778450B2 (en) 1999-07-02 2004-12-09 Eisai R&D Management Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
JP3914434B2 (ja) 1999-08-31 2007-05-16 ヴァンダービルト ユニヴァーシティ Ａ２ｂアデノシン受容体の選択的アンタゴニスト
CA2400206A1 (en) 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
ATE293962T1 (de) 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
DE60107835T2 (de) 2000-04-26 2005-12-22 Eisai Co., Ltd. Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide
EP1308441B1 (en) 2000-08-11 2009-10-07 Eisai R&D Management Co., Ltd. 2-aminopyridine compounds and use thereof as drugs
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
HUP0302173A2 (hu) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
AU2001292906B2 (en) 2000-09-19 2007-08-16 Novartis Vaccines And Diagnostics, Inc. Characterization of the GSK-3beta protein and methods of use thereof
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
ES2247356T3 (es) 2001-06-29 2006-03-01 Cv Therapeutics, Inc. Derivados de purina com antagonistas del receptor a2b de adenosina.
TWI330183B (ru) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
EP1444233B1 (en) 2001-11-09 2011-08-17 Gilead Palo Alto, Inc. A2b adenosine receptor antagonists
US20050043315A1 (en) 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
WO2003063800A2 (en) 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
WO2003068773A1 (en) 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
CN1671716A (zh) 2002-06-12 2005-09-21 拜奥根Idec马萨诸塞公司 用腺苷受体拮抗剂治疗缺血再灌注损伤的方法
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
EP1549614A4 (en) 2002-10-03 2008-04-16 Targegen Inc VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
WO2004076450A1 (en) 2003-02-27 2004-09-10 J. Uriach Y Compañia S.A. Pyrazolopyridine derivates
WO2004106337A1 (en) 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
EP2295434B1 (en) 2003-08-25 2015-09-30 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W Pyrimidines substituted in the 2,4,6 positions and their different uses
RU2006118325A (ru) * 2003-10-27 2007-12-10 Астеллас Фарма Инк. (Jp) Производные пиразина и их фармацевтическое применение
ATE419252T1 (de) 2003-10-31 2009-01-15 Cv Therapeutics Inc Antagonisten des a2b-adenosinrezeptors
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
ES2303776B1 (es) 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.

Also Published As

Publication number Publication date
KR20080040681A (ko) 2008-05-08
ECSP088113A (es) 2008-02-20
AR056008A1 (es) 2007-09-12
ES2270715B1 (es) 2008-04-01
TW200728299A (en) 2007-08-01
SG162805A1 (en) 2010-07-29
ES2270715A1 (es) 2007-04-01
MX2008001035A (es) 2008-03-14
NO20080451L (no) 2008-02-11
RU2008107264A (ru) 2009-09-10
US7790728B2 (en) 2010-09-07
US20100273757A1 (en) 2010-10-28
IL188725A0 (en) 2008-08-07
RU2417994C2 (ru) 2011-05-10
ZA200800353B (en) 2008-12-31
CN101268064A (zh) 2008-09-17
PE20070407A1 (es) 2007-05-12
JP2009502837A (ja) 2009-01-29
US20090042891A1 (en) 2009-02-12
CA2616428A1 (en) 2007-02-15
EP1922313A1 (en) 2008-05-21
NZ565150A (en) 2011-02-25
WO2007017096A1 (en) 2007-02-15
UY29672A1 (es) 2007-01-31
AU2006278875A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
UA93883C2 (ru) Производные пиразина, полезные kak антагонисты аденозинового рецептора
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
MX2007001289A (es) Piridinas condensadas como inhibidores de cinasa.
TN2010000101A1 (en) Fungicidal 2-alkylthio-2-quinolinyloxy -acetamide derivatives
MX2009010595A (es) Derivados de pirrolopirimidina.
TN2010000064A1 (en) Novel herbicides
TN2010000102A1 (en) Novel fungicides
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
TW200611907A (en) Fused heterocyclic compound
GB0508318D0 (en) Organic compounds
MX2010001364A (es) Derivados de ciclopentandiona puenteados triciclicos como herbicidas.
GB0508314D0 (en) Organic compounds
MX2009007302A (es) Derivados de purina.
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
TW200638930A (en) Acetylene derivatives
SG153811A1 (en) Quinazolinone derivatives useful as vanilloid antagonists
TW200740814A (en) Compounds
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
UA101963C2 (en) 4-amino-pyrimidine derivatives
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
WO2007000340A8 (en) Bicyclic derivatives as p38 kinase inhibitors
WO2009007115A8 (en) Tropane derivatives useful as pesticides
HK1115500A1 (en) Isoquinolines as igf-1r inhibitors
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists